Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
HYCOFENIX is an oral solution combining guaifenesin (expectorant), hydrocodone bitartrate (opioid cough suppressant), and pseudoephedrine hydrochloride (decongestant) for symptomatic relief of cough and congestion. This fixed-dose combination targets patients with productive cough and nasal congestion associated with upper respiratory conditions. The formulation leverages synergistic action of three well-established agents in a single liquid delivery system.
Product is in peak commercial phase with moderate competitive pressure (30/100), suggesting stable demand and adequate team resourcing for brand defense.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on HYCOFENIX offers stable, peak-phase commercial opportunity with focus on brand defense, channel management, and regulatory compliance in the competitive cough-and-cold market. Career trajectory emphasizes execution excellence, formulary positioning, and payer negotiation rather than innovation or launch strategy.
Worked on HYCOFENIX at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.